2025 HCPCS code J2210
Effective Date: N/A Drugs Administered Other than Oral Method - Drugs, Administered by Injection Feed
Injection, methylergonovine maleate, up to 0.2 mg
Modifiers may be applicable depending on the specific circumstances of the administration.
Medical necessity for J2210 is established by the presence of postpartum bleeding or uterine atony that requires treatment with methylergonovine maleate.
In simple words: This code covers the medication methylergonovine, given as a shot, to help stop bleeding after childbirth. It does not include the cost of giving the injection.
Methylergonovine maleate is an ergot alkaloid used to control postpartum bleeding. One unit of this code represents up to 0.2 mg of methylergonovine maleate administered intravenously or intramuscularly. This code represents the drug only and not its administration.
Example 1: A patient experiences postpartum hemorrhage after a vaginal delivery. Methylergonovine maleate (J2210) is administered intramuscularly to control the bleeding. , Following a cesarean section, a patient develops uterine atony. J2210 is given intravenously to promote uterine contractions and reduce bleeding. , A patient has retained placental fragments after delivery, leading to excessive bleeding. Methylergonovine (J2210) is administered to help expel the fragments and control the hemorrhage.
Documentation should support the medical necessity for the use of methylergonovine maleate, such as postpartum hemorrhage or uterine atony. The dosage administered should also be documented. The route of administration (IV or IM) must be specified.
- Specialties:Obstetrics and Gynecology
- Place of Service:Inpatient Hospital, Birthing Center